Enovis (NYSE:ENOV) Upgraded to Strong-Buy at UBS Group

UBS Group upgraded shares of Enovis (NYSE:ENOV) to a strong-buy rating in a report published on Tuesday morning,Zacks.com reports.

Other equities analysts have also issued research reports about the company. BTIG Research reissued a “buy” rating and issued a $39.00 price objective on shares of Enovis in a research note on Friday, May 22nd. BMO Capital Markets began coverage on Enovis in a report on Wednesday, July 8th. They issued an “outperform” rating and a $29.00 price target for the company. Weiss Ratings upgraded shares of Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, July 21st. Zacks Research lowered shares of Enovis from a “hold” rating to a “strong sell” rating in a report on Tuesday, June 30th. Finally, Wall Street Zen upgraded shares of Enovis from a “hold” rating to a “buy” rating in a research report on Monday, July 6th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $41.86.

Enovis Stock Performance

NYSE ENOV opened at $30.18 on Tuesday. The firm has a market cap of $1.74 billion, a price-to-earnings ratio of -1.52 and a beta of 1.39. The company has a 50 day moving average of $23.86 and a 200-day moving average of $23.78. The company has a current ratio of 2.04, a quick ratio of 1.05 and a debt-to-equity ratio of 0.87. Enovis has a 1-year low of $19.14 and a 1-year high of $34.28.

Enovis (NYSE:ENOV) last announced its earnings results on Thursday, May 7th. The company reported $0.89 EPS for the quarter, topping the consensus estimate of $0.82 by $0.07. The business had revenue of $589.15 million for the quarter, compared to the consensus estimate of $572.02 million. Enovis had a positive return on equity of 10.32% and a negative net margin of 49.92%.Enovis’s revenue was up 5.4% compared to the same quarter last year. During the same period in the previous year, the business earned $0.81 EPS. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, equities analysts forecast that Enovis will post 3.12 earnings per share for the current fiscal year.

Insider Activity at Enovis

In other news, insider Oliver Engert purchased 1,200 shares of the business’s stock in a transaction dated Thursday, June 11th. The shares were bought at an average cost of $21.62 per share, for a total transaction of $25,944.00. Following the completion of the acquisition, the insider directly owned 51,840 shares in the company, valued at approximately $1,120,780.80. This trade represents a 2.37% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have acquired 4,200 shares of company stock worth $92,084 in the last quarter. Company insiders own 2.90% of the company’s stock.

Institutional Trading of Enovis

A number of hedge funds and other institutional investors have recently modified their holdings of ENOV. Arax Advisory Partners acquired a new position in Enovis during the fourth quarter valued at approximately $29,000. EverSource Wealth Advisors LLC raised its stake in shares of Enovis by 125.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after purchasing an additional 707 shares in the last quarter. Danske Bank A S acquired a new stake in shares of Enovis in the 3rd quarter valued at approximately $64,000. iSAM Funds UK Ltd acquired a new position in Enovis during the third quarter worth $80,000. Finally, Brown Brothers Harriman & Co. acquired a new position in Enovis during the third quarter worth $90,000. Institutional investors and hedge funds own 98.45% of the company’s stock.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.